EGFR StripAssay®

Non-small cell lung cancers (NSCLC) comprise approximately 85% of all lung cancers. Somatic mutations in the epidermal growth factor receptor tyrosine kinase (EGFR-TK) domain influence the treatment wEth EGFR-TK inhibElors. The EGER StripAssay ID identifies the most important mutations relevant for anti EGFR-TK therapy